A Phase 3 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 51st largest by enrollment, is one of 20 that started in 2015, is one of 56 in phase 3, and was the 147th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 20 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 37th largest by enrollment of the 97 interventional ones that give a count, is one of 25 that started in 2015, is one of 35 in phase 3, and was the 74th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in adults with chronic hepatitis C virus (HCV) infection.
Key Inclusion Criteria:
Key Exclusion Criteria:
For -1/HCV co-infected individuals:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
Drug: LDV/SOF
Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
Drug: LDV/SOF
Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
Drug: LDV/SOF · Drug: RBV
90/400 mg FDC tablet administered orally once daily
Also known as: Harvoni®, GS-5885/GS-7977
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
Time frame: Posttreatment Week 12
Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE)
Time frame: Up to 12 weeks
Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.
Time frame: Posttreatment Weeks 4 and 24
Percentage of Participants With HCV RNA < LLOQ on Treatment
Time frame: Up to 12 weeks
HCV RNA Change From Day 1
Time frame: Up to 12 weeks
Percentage of Participants With Virologic Failure
Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement
Time frame: Up to Posttreatment Week 24
Percentage of HIV/HCV- Coinfected Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4
Time frame: Up to Posttreatment Week 4
For HIV/HCV- Coinfected Participants, Change From Baseline in CD4 T-cell Count at the End of Treatment and Posttreatment Week 4
Time frame: Up to Posttreatment Week 4
Participants were enrolled at study sites in Russia and Estonia. The first participant was screened on 17 June 2015. The last study visit occurred on 30 June 2016.
| Milestone | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Started | 67 | 59 | 27 |
| Completed | 67 | 57 | 26 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) | 100.0 (94.6 to 100.0) | 96.6 (88.3 to 99.6) | 96.3 (81.0 to 99.9) |
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to Any Adverse Event (AE) | 0 | 0 | 0 |
SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| SVR4 | 100.0 (94.6 to 100.0) | 96.6 (88.3 to 99.6) | 96.3 (81.0 to 99.9) |
| SVR24 | 100.0 (94.6 to 100.0) | 96.6 (88.3 to 99.6) | 96.3 (81.0 to 99.9) |
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Week 1 | 20.9 (11.9 to 32.6) | 39.0 (26.5 to 52.6) | 3.7 (0.1 to 19.0) |
| Week 2 | 65.7 (53.1 to 76.8) | 69.5 (56.1 to 80.8) | 59.3 (38.8 to 77.6) |
| Week 4 | 100.0 (94.6 to 100.0) | 96.6 (88.3 to 99.6) | 88.9 (70.8 to 97.6) |
| Week 8 | 100.0 (94.6 to 100.0) | 98.3 (90.9 to 100.0) | 100.0 (87.2 to 100.0) |
| Week 12 | NA (NA to NA) | NA (NA to NA) | 100.0 (87.2 to 100.0) |
| log10 IU/mL | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Week 1 | -3.97 ± 0.675 | -4.34 ± 0.626 | -4.12 ± 0.582 |
| Week 2 | -4.50 ± 0.687 | -4.76 ± 0.522 | -4.83 ± 0.630 |
| Week 4 | -4.74 ± 0.723 | -4.89 ± 0.534 | -5.08 ± 0.642 |
| Week 8 | -4.74 ± 0.723 | -4.91 ± 0.536 | -5.11 ± 0.671 |
| Week 12 | NA ± NA | NA ± NA | -5.11 ± 0.671 |
Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| Percentage of Participants With Virologic Failure | 0 | 3.4 | 3.7 |
| percentage of participants | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) |
|---|---|
| Week 4 | 100.0 |
| Week 8 | 100.0 |
| Posttreatment Week 4 | 97.2 |
| cells/µL | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected, ARV- Naive) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected, ARV Experienced) |
|---|---|---|
| Change at Week 4 | 47 ± 120.5 | 159 ± 114.9 |
| Change at Week 8 | 45 ± 122.7 | 202 ± 178.1 |
| Change at Posttreatment Week 4 | 74 ± 117.8 | 172 ± 114.1 |
Collected over Up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDV/SOF 8 Weeks (TN, HCV-monoinfected) | 0/67 (0%) | 0/67 (0%) | 5/67 (7.5%) |
| LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | 0/59 (0%) | 0/59 (0%) | 2/59 (3.4%) |
| LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | 0/27 (0%) | 0/27 (0%) | 8/27 (29.6%) |
| Event | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) |
|---|---|---|---|
| HeadacheNervous system disorders | 4/67 | 0/59 | 4/27 |
| DyspepsiaGastrointestinal disorders | 0/67 | 0/59 | 3/27 |
| Abdominal pain upperGastrointestinal disorders | 1/67 | 1/59 | 2/27 |
| AstheniaGeneral disorders | 1/67 | 0/59 | 2/27 |
| Blood bilirubin increasedInvestigations | 0/67 | 0/59 | 2/27 |
| IrritabilityPsychiatric disorders | 0/67 | 1/59 | 2/27 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| Mean | 42 ± 12.6 | 34 ± 5.5 | 47 ± 11.2 | 40 ± 11.1 |
| Sex: Female, Male(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| Female | 33 | 25 | 9 | 67 |
| Male | 34 | 34 | 18 | 86 |
| Race/Ethnicity, Customized(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| White | 66 | 59 | 27 | 152 |
| Asian | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 67 | 59 | 27 | 153 |
| Region of Enrollment(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| Russian Federation | 61 | 47 | 27 | 135 |
| Estonia | 6 | 12 | 0 | 18 |
| IL28b Status(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| CC | 17 | 9 | 7 | 33 |
| CT | 41 | 41 | 18 | 100 |
| TT | 9 | 9 | 2 | 20 |
| HCV RNA(log10 IU/mL) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| Mean | 5.9 ± 0.72 | 6.1 ± 0.54 | 6.3 ± 0.67 | 6.0 ± 0.66 |
| HCV RNA Category(Participants) | LDV/SOF 8 Weeks (TN, HCV-monoinfected) | LDV/SOF 8 Weeks (TN, HCV/HIV-coinfected) | LDV/SOF + RBV 12 Weeks (TE, SOF-treated, HCV-monoinfected) | Total |
|---|---|---|---|---|
| < 800,000 IU/mL | 29 | 23 | 8 | 60 |
| ≥ 800,000 IU/mL | 38 | 36 | 19 | 93 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jun 2015 to primary completion in Mar 2016, 9 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 9 months is below that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin